Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar InspectionsJuly 17th 2022
Julie M. Reed, the executive director of the Biosimilars Forum, dives into the efforts that the Forum is taking to ensure that FDA can catch up on their inspections backlog and get biosimilar approvals back on track.
Gillian Woollett Speaks on Where Biosimilar Conversations Need to Go Moving ForwardJune 26th 2022
Although a lot of discussion regarding biosimilars has focussed on patient access, we need to divert more attention to the reliability of companies making biosimilar products, said Gillian Woollett, MA, DPhil, vice president and head of regulatory strategy and policy at Samsung Bioepis.
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg ExplainsJune 22nd 2022
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing number of biosimilars referencing Humira (adalimumab) that are expected to enter the market in 2023 and beyond.
Julie Reed: Biosimilar Policies Legislators Should Be PrioritizingJune 19th 2022
The Biden administration must follow through on its promises, and Congressional leaders must do more to push through bipartisan biosimilar policies to encourage better adoption and lower drug costs, according to Julie M. Reed, the executive director of the Biosimilars Forum.